February 7, 2014 — Results from several late-breaking clinical trials will be presented during the American College of Cardiology (ACC) 2014 annual meeting March 29-31. These will be featured during five late-breaking clinical trial sessions.
Joint ACC/JACC Late-Breaking Clinical Trials
Session 451, Saturday, March 29, 8–10 a.m., Hall D (Main Tent)
- A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
- The main results of SYMPLICITY HTN-3 renal denervation trial
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 402, Sunday, March 30, 8–9:15 a.m., Hall D (Main Tent)
- Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) Trial
- The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy - 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Evaluation of the Dual PPAR-?/? Agonist Aleglitazar to Reduce Cardiovascular Events in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus: the AleCardio Trial
- Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the Nobori Biolimus-Eluting versus Xience/Promus Everolimus-eluting Stent Trial (NEXT)
- A Phase 3 Double-blind, Randomized Study to Assess the Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin
Late-Breaking Clinical Trials III
Session 403, Sunday, March 30, 10:45 a.m.–noon, Hall D (Main Tent)
- Efficacy And Safety Of Colchicine In Patients With Multiple Recurrences Of Pericarditis: Results Of A Multicenter, Double-blind, Placebo-controlled, Randomized Study (corp-2 Trial)
- The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
- One Year Follow-up of the Melody Transcatheter Pulmonary Valve Multicenter Post Approval Study
- Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
- Negative High-Sensitive Troponins in the Emergency Department and Risk of Myocardial Infarction
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 404, Monday, March 31, 8–9:15 a.m., Hall D (Main Tent)
- The Impact of Acetyl-Salicylic Acid on Major Arterial and Venous Complications in Patients Undergoing Noncardiac Surgery
- A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery
- Steroids in Cardiac Surgery Trial (SIRS)
- Metformin in Acute Myocardial Infarction
- Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
Late-Breaking Clinical Trials V: TCT@ACC-i2
Session 405, Monday, March 31, 10:45 a.m.–noon, Hall D (Main Tent)
- One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
- A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement - The CHOICE Trial
- Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention: A Unique Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Designed to Reflect Real-World, Contemporary Practice
- Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial
- Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial
Late-Breaking Clinical Sessions Deep Dive
Session 406, Monday, March 31, 10:45 a.m.–12:15 p.m., Hall D (Main Tent)
- Hear key highlights of the LBCTs presented throughout ACC.14 and learn about what it all means for you and your patients
For more information: accscientificsession.cardiosource.org
April 11, 2024 
